Adam Feuerstein
Immunogen has a pipeline of its own proprietary cancer drugs, but the market isn't going to give them much credit until further progress is made with T-DM1. The Genentech go/no-go decision is key. So far, there hasn't been any indication that Genentech won't move forward into phase III, but you can't be sure until the announcement is made.
I'd also expect Immunogen to raise money if T-DM1 moves forward and the stock pops as a result. As for Titan, wasn't the retirement of founder and chairman Lou Bucalo strangely timed? After all, why would he leave now, with the U.S. Food and Drug Administration expected to issue an approval decision in July on the company's schizophrenia drug Fanapta, also known as iloperidone. (Vanda Pharmaceuticals (VNDA Quote - Cramer on VNDA - Stock Picks) is in charge of Fanapta's development, with Titan receiving royalties.) I'm not a fan of Fanapta, as I've stated in the past. It's a me-too drug in a regulatory environment that frowns on such things. I don't expect the drug to get a first-time approval from the FDA. And yes, I know there's more to the Titan story than Fanapta, but not too much more and certainly not until the FDA rules on Fanapta.Leo G. makes a prediction: "Avant Immunotherapeutics (AVAN Quote - Cramer on AVAN - Stock Picks) will soon be the biggest winning stock of 2008, how about doing a write up on it?" I did write about Avant after Pfizer (PFE Quote - Cramer on PFE - Stock Picks) licensed the company's brain cancer vaccine, CDX-110. There will be data presented on CDX-110 at the ASCO meeting. Stay tuned. As I wrote this week, ASCO research abstracts will be released to the public on May 15. The CDX-110 abstract number is 2011, titled, "Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM."
RSS
